Today: 9 June 2026
Xanadu Jumps 20% After Quantum Selloff, Filing Remains Over XNDU
20 May 2026
2 mins read

Xanadu Jumps 20% After Quantum Selloff, Filing Remains Over XNDU

TORONTO, May 20, 2026, 17:09 (EDT)

Xanadu Quantum Technologies shares surged on Nasdaq Wednesday, with the stock rebounding after a tough May. The Class B shares traded between $11.70 and $14.68, and were recently quoted at $14.13, up $2.39, or 20.4%.

XNDU has turned into a kind of bellwether for how the public market is taking to early-stage quantum stocks—lots of technology promises, not much revenue yet, and a share structure still working itself out after a blank-cheque merger. A SPAC, or special purpose acquisition company, is a listed shell company for taking another firm public via merger.

Stocks rallied Wednesday, with the Nasdaq Composite up 1.6%, the S&P 500 climbing 1.1% and the Dow up 1.3%. Investors rotated back into growth names as oil dropped.

Other quantum stocks moved up as well, pointing to a broader rally beyond a single company. IonQ was up around 8.3%. D-Wave Quantum picked up 6.0%. Rigetti Computing gained roughly 5.7%, according to market data.

Xanadu’s overhang is big. In May, the company filed a prospectus for as much as 293.7 million Class B subordinate voting shares from selling securityholders. That includes shares linked to conversions of multiple-voting stock, private deals, and founder shares. Xanadu said it is not getting proceeds from those share sales except for cash if warrants are exercised.

Stock could see more shares hit the market, even as the business stays the same. The company’s quarterly filing listed 43.3 million Class B shares as outstanding on March 31. There were also 255.2 million Class A multiple-voting shares, which are convertible into Class B shares.

Xanadu reported first-quarter revenue of $2.83 million, up from $699,000 a year ago. But net loss also got bigger, rising to $20.6 million from $12.2 million. Cash and cash equivalents reached $272.5 million as of March 31, with about $301.6 million coming in from the reverse recap and private placement.

Xanadu Founder and CEO Christian Weedbrook said after the results that the company was “not measuring success in quarters.” CFO Michael Trzupek said Xanadu is “in an investment phase.” The company said it’s in discussions for up to around $285 million in proposed support from Ottawa and Ontario. Xanadu Quantum Technologies Limited

Xanadu is going after photonic quantum computing—using light for quantum data. The filing shows most of what’s out now is still software, simulators, cloud services and test projects with partners, with no widescale sales of full quantum computers yet.

The downside is tough to ignore. Xanadu said in its prospectus that its tech is still early and it hasn’t built a commercial-scale, fault-tolerant quantum computer yet. Fault-tolerant systems keep running even with errors. Xanadu also told investors it might miss its 2029-2030 goal to reach 100,000 physical qubits and up to 500 logical qubits. Qubits are the basic units in quantum computing.

The funding angle is in play. Kat Liu, vice president at IPOX, told Reuters last year that SPAC listings can give research-focused quantum companies a “large, single-tranche capital infusion.” But she said public markets later want evidence that new cash is driving technical gains. Reuters

Upcoming dates for Xanadu are on the calendar. The investor page shows the company is set for the CIBC Technology & Innovation Conference and the CG Virtual Quantum Symposium on May 21. The TD Cowen TMT event is after that, on May 28. Shares bounced on Wednesday, but the issues around share supply and the delay in commercial quantum revenue are still there.

Stock Market Today

  • NYSE Update: HUD Sec. Turner Highlights National Homeownership Month Amid Market Moves
    June 9, 2026, 10:01 AM EDT. The New York Stock Exchange (NYSE) highlighted key market developments on June 9, 2026, including chip stocks boosting the S&P 500 early in the week. Fintech firm Thunes opened a new office in New York City to enhance global money movement solutions for U.S. businesses. Philips released its 2026 Future Health Index U.S. report. U.S. Secretary of Housing and Urban Development Scott Turner will appear on NYSE Live to discuss efforts to empower homebuilders and ease regulations, spotlighting National Homeownership Month. Cloudflare held its 2026 Investor Day, while Man Group rang the NYSE Closing Bell the previous day. The NYSE encourages investors to access the TV App for detailed market insights and IPO activity.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
FuelCell Energy surges as AI-fueled rally hits again, analysts wary
Previous Story

FuelCell Energy surges as AI-fueled rally hits again, analysts wary

SPAC ETF Up as SpaceX Heads for SPCX Ticker
Next Story

SPAC ETF Up as SpaceX Heads for SPCX Ticker

Go toTop